Search
FEMY · Company research

Femasys Inc. Common Stock (FEMY): Stock News & Events

Recent company-linked news records available in the database.

Main stock researchCompare stocks
RESEARCH CONTEXT

Understand the numbers

Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.

18records availableHealthcare

Stock News & Events data

Database-backed records only

18 rows
titlesummaryurlsourcepublished atsentimentsentiment scorerelevance score
Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNsFemasys Inc. announced a partnership with SandsRx Pharmacy, the first in a planned network of specialty pharmacy partnerships, to provide medication coordination and preferred pricing for OB/GYN practices offering FemaSeed fertility treatment. The partnership aims to support the integration of Femasys' fertility portfolio into primary care settings, making fertility treatment more accessible and affordable.View source ↗GlobeNewswire Inc.Oct 20, 2026bullish11
A fund manager reports a passive 468,750-share stake in Femasys (FEMY). - Stock TitanA fund manager reports a passive 468,750-share stake in Femasys (FEMY). Stock TitanView source ↗Stock TitanOct 15, 2026neutral00.6
Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth ControlFemasys Inc. announced it has doubled the number of actively enrolling sites in its FemBloc FINALE Pivotal Trial to twelve across the United States, including prominent academic centers like Baylor Research Institute and Columbia University Medical Center. The expansion, enabled by August 2026 financing, demonstrates progress in the company's U.S. regulatory strategy for FDA approval of FemBloc, a non-surgical permanent birth control solution already approved in Europe, UK, and New Zealand.View source ↗GlobeNewswire Inc.Oct 14, 2026bullish11
Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth ControlFemasys Inc. announced it has doubled the number of actively enrolling sites in its FemBloc FINALE Pivotal Trial to twelve across the United States, including prominent academic centers like Baylor Research Institute and Columbia University Medical Center. The expansion, enabled by August 2026 financing, demonstrates progress in the company's U.S. regulatory strategy for FDA approval of FemBloc, a non-surgical permanent birth control solution already approved in Europe, UK, and New Zealand.View source ↗GlobeNewswire Inc.Oct 14, 2026bullish11
Femasys Inc. (FEMY) Slides 12.5% to $1.75 as Shares Press Toward Key Support - Volatility Smile - www.dars.gov.etFemasys Inc. (FEMY) Slides 12.5% to $1.75 as Shares Press Toward Key Support - Volatility Smile www.dars.gov.etView source ↗www.dars.gov.etOct 13, 2026neutral00.6
Femasys Inc. (FEMY) Slides 12.5% to $1.75 as Shares Press Toward Key Support - Golden Cross - https://www.siam.in/Femasys Inc. (FEMY) Slides 12.5% to $1.75 as Shares Press Toward Key Support - Golden Cross https://www.siam.in/View source ↗https://www.siam.in/Oct 13, 2026neutral00.6
Femasys Inc. (FEMY) Stock Price, News, Quote & History - Yahoo! Finance CanadaFemasys Inc. (FEMY) Stock Price, News, Quote & History Yahoo! Finance CanadaView source ↗Yahoo! Finance CanadaOct 9, 2026neutral00.6
A fertility treatment and an in-office fallopian tube test will be shown in Baltimore. - Stock TitanA fertility treatment and an in-office fallopian tube test will be shown in Baltimore. Stock TitanView source ↗Stock TitanOct 8, 2026neutral00.6
Femasys (FEMY) Slips 2.64% to $2.02 as Shares Drift Toward Lower Support - GEX Level - https://www.dars.gov.et/Femasys (FEMY) Slips 2.64% to $2.02 as Shares Drift Toward Lower Support - GEX Level https://www.dars.gov.et/View source ↗https://www.dars.gov.et/Oct 7, 2026neutral00.6
FEMASYS INC SEC Filing (Sep 29, 2026) - Stock TitanFEMASYS INC SEC Filing (Sep 29, 2026) Stock TitanView source ↗Stock TitanSep 29, 2026neutral00.6
FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential - StocktwitsFEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential StocktwitsView source ↗StocktwitsAug 19, 2026neutral00.6
FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential - Yahoo FinanceFEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential Yahoo FinanceView source ↗Yahoo FinanceAug 19, 2026neutral00.6
Why Is Femasys Stock Soaring Today? - Femasys (NASDAQ:FEMY) - BenzingaWhy Is Femasys Stock Soaring Today? - Femasys (NASDAQ:FEMY) BenzingaView source ↗BenzingaAug 19, 2026neutral00.6
$FEMY stock is up 22% today. Here's what we see in our data. - Quiver Quantitative$FEMY stock is up 22% today. Here's what we see in our data. Quiver QuantitativeView source ↗Quiver QuantitativeAug 19, 2026neutral00.6
Insider Purchase: Chief Clinical-Medical Affairs of $FEMY Buys 3,125 Shares | FEMY Stock News - Quiver QuantitativeInsider Purchase: Chief Clinical-Medical Affairs of $FEMY Buys 3,125 Shares | FEMY Stock News Quiver QuantitativeView source ↗Quiver QuantitativeAug 12, 2026neutral00.6
Femasys COO John Canning buys $14,000 in FEMY stock - Investing.comFemasys COO John Canning buys $14,000 in FEMY stock Investing.comView source ↗Investing.comAug 11, 2026neutral00.6
Femasys CEO Kathy Lee-Sepsick buys $50,000 in FEMY stock - Investing.comFemasys CEO Kathy Lee-Sepsick buys $50,000 in FEMY stock Investing.comView source ↗Investing.comAug 11, 2026neutral00.6
Femasys to implement 1-for-20 reverse stock split; trading symbol FEMY unchanged - TradingViewFemasys to implement 1-for-20 reverse stock split; trading symbol FEMY unchanged TradingViewView source ↗TradingViewJun 4, 2026neutral00.6

Informational research only, not financial advice. Forecasts are uncertain and can be wrong.